Business
Grant of Options
Grant of Options.
About this update from Creo Medical Group Plc
[{"type":"text","content":"\n\nCreo Medical Group plc\n(\"Creo\", the \"Company\" or the \"Group\")\n \nGrant of Options\n \nCreo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces that on 24 March 2025, it granted options over an aggregate 6,474,713 ordinary shares of £0.001 in the Company (the \"Options\") to certain Directors of the Company as follows:\n \n\n\n\n\nName of Director\n\n\nShare Options Granted\n\n\nExercise Price\n\n\nTotal no. of options over ordinary shares now held\n \n\n\n\n\nCraig Gulliford\n\n\n2,062,500\n\n\n£0.13125\n\n\n9,970,001\n\n\n\n\nChristopher Hancock\n\n\n1,384,063\n\n\n£0.13125\n\n\n7,832,637\n\n\n\n\nRichard Rees\n\n\n1,410,938\n\n\n£0.13125\n\n\n6,066,870\n\n\n\n\nDavid Woods\n\n\n1,617,212\n\n\n£0.13125\n\n\n3,712,322\n\n\n\n\n \nVesting of the options is subject to performance conditions through to December 2027.\n \nFor further information please contact: \n \n\n\n\n\nCreo Medical Group plc\n\n\nwww.creomedical.com\n\n\n\n\nRichard Craven, Company Secretary\n\n\nVia Walbrook PR\n\n\n\n\n\n\n\n\n\n\n\n\nDeutsche Numis (Nominated Adviser, sole Broker and Financial Adviser)\nFreddie Barnfield / Duncan Monteith / Euan Brown / Sher Shah\n\n\n+44 (0)20 7260 1000\n\n\n\n\n \n\n\n\n\n\n\n\nWalbrook PR Ltd\n\n\nTel: +44 (0)20 7933 8780 or [email protected]\n\n\n\n\nPaul McManus / Alice Woodings\nPhillip Marriage\n\n\nMob: +44 (0)7980 541 893 / +44 (0)7407 804 654\nMob: +44 (0)7867 984 082\n\n\n\n\n\n\n\n\n\n \n\n \nAbout Creo Medical\nCreo is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.\n \nThe Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation, and ablation of tissue. ...